C. Setze

发表

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Advances in Therapy.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

M. Davidson, M. Kashyap, C. Setze, 2009, Atherosclerosis.

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial

C. Ballantyne, R. Rosenson, S. Nicholls, 2012, Cardiovascular Drugs and Therapy.

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis

S. Mohiuddin, K. Thakker, C. Setze, 2011, Current medical research and opinion.

Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study

R. Rosenson, L. Williams, N. Khurmi, 2010, Cardiovascular Drugs and Therapy.

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

K. Chayama, M. Kurosaki, T. Pilot‐Matias, 2015, Hepatology.

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

K. Chayama, Y. Karino, M. Patwardhan, 2015, Hepatology.

In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir , an Inhibitor of Hepatitis C Virus NS 5 A

A. Molla, T. Pilot‐Matias, T. Reisch, 2015 .

In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

A. Molla, T. Pilot‐Matias, T. Reisch, 2014, Antimicrobial Agents and Chemotherapy.

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2015, Antimicrobial Agents and Chemotherapy.

1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS

T. Pilot‐Matias, W. Xie, E. Lawitz, 2012 .

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Journal of medical virology.

An interferon-free antiviral regimen for HCV after liver transplantation.

X. Forns, T. Pilot‐Matias, N. Terrault, 2014, The New England journal of medicine.

Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.

A. Goldberg, H. Knapp, C. Setze, 2010, American heart journal.

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.

R. Rosenson, M. Davidson, K. Thakker, 2012, Journal of clinical lipidology.

One-Year Efficacy and Safety of Rosuvastatin + Fenofibric Acid Combination Therapy in Patients with Mixed Dyslipidemia

K. Ferdinand, M. Davidson, C. Setze, 2012, American Journal of Cardiovascular Drugs.

Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies

C. Pepine, L. Williams, A. Gold, 2010, Clinical cardiology.

A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.

L. Williams, C. Setze, D. Weinstein, 2013, Clinical therapeutics.

O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION

X. Forns, N. Terrault, F. Gordon, 2014 .

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides

C. Ballantyne, K. Thakker, C. Setze, 2011, Cardiovascular Drugs and Therapy.

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins

H. Bays, M. Davidson, C. Setze, 2008, Clinical drug investigation.

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

B. Strober, A. Gottlieb, K. Papp, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.

A. Goldberg, C. Pepine, V. Bittner, 2011, The American journal of cardiology.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

C. Pepine, S. Mohiuddin, C. Setze, 2009, American heart journal.

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus

R. Rosenson, L. Williams, B. Hirshberg, 2010, Cardiovascular Drugs and Therapy.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.

C. Ballantyne, A. Goldberg, H. Bays, 2009, The American journal of cardiology.

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.

H. Bays, S. Mohiuddin, C. Setze, 2008, Journal of clinical lipidology.

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia

J. Mckenney, H. Bays, K. Thakker, 2010, Diabetes Care.

Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination

M. Kipnes, C. Setze, E. Roth, 2010, Clinical Drug Investigation.

Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.

A. Goldberg, C. Pepine, M. Davidson, 2009, Journal of clinical lipidology.

Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus

K. Cusi, M. Davidson, K. Thakker, 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

1190 STUDY OF ABT-267 2-DAY MONOTHERAPY FOLLOWED BY 12-WEEK COMBINATION THERAPY IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION

M. Epstein, T. Pilot‐Matias, T. Marbury, 2013 .

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

T. Pilot‐Matias, T. Marbury, W. Xie, 2012 .

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

C. Stedman, T. Pilot‐Matias, A. Tran, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ombitasvir/Paritaprevir/Ritonavir with Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egyptian Adults with Chronic HCV Genotype 4 Infection (Agate-II)

G. Shiha, I. Waked, G. Esmat, 2016 .

Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia

J. Mckenney, L. Williams, A. Gold, 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.